These results are similar to those reported in other preclinical studies that investigated HD treatments to induce autophagy and lower mHtt aggregates including those using L807mts to inhibit GSK-3 (glycogen synthase kinase-3), SAFit2 to inhibit FKFB5 (FK506 binding protein 5), ginkgolic acid to inhibit SUMOylation, metformin to activate AMPK, and rapamycin or trehalose to inhibit mTOR [5,[14], [15], [16], [17],19,20]. Here, MTOR is linked to Huntington disease.